At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 21, 2026 at 10:26 ET
Immatics announced that four of its abstracts have been accepted for oral presentation at the 2026 ASCO Annual Meeting, featuring clinical data from its PRAME-targeted cell therapies (anzu-cel, IMA203CD8) and MAGEA4/8 bispecific (IMA401) across multiple solid tumors. The presentations include updated Phase 1b and Phase 1a/1b data in melanoma, gynecologic cancers, synovial sarcoma, and first-in-human results for IMA401. This visibility at a top oncology conference highlights clinical progress in its core pipeline programs.
- Four abstracts accepted for oral presentation at ASCO 2026, a high-impact oncology conference
- Data includes updated Phase 1b results for anzu-cel in advanced melanoma and Phase 1a/1b data for IMA203CD8 (GEN2) in gynecologic cancers
- First-in-human results for IMA401, a MAGEA4/8 bispecific, to be presented across multiple solid tumors
- Presentations span melanoma, gynecologic cancers, and synovial sarcoma, demonstrating broad applicability of PRAME-targeted therapies
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access